Autres langues JW (Cayman) Therapeutics Co. Ltd

Actions

2126

KYG5210T1040

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:22 10/05/2024			Varia. 5j.	Varia. 1 janv.
2,43 ^HKD	+29,95%		+27,89%	+7,52%

20/03	JW (Cayman) Therapeutics réduit sa perte pour l'exercice 2023	MT
20/03	JW (Cayman) Therapeutics Co. Ltd présente ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023	20/03
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
China Regulator Accepts JK Therapeutics' Supplemental License Application for Lymphoma Therapy	05/01
JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva in Patients with Relapsed or Refractory Mantle Cell Lymphoma	04/01
JW (Cayman) Therapeutics Signs Collaboration Deal for Development of Autoimmune Disease Treatment	03/01
JW Therapeutics Announces Exclusive Collaboration with 2Seventy Bio for Autoimmune Disease Car-T Therapy	02/01
JW Therapeutics CFO Resigns	18/12
JW Therapeutics Co. Ltd Announces Resignation of Xin Fu as Chief Financial Officer	15/12
JW (Cayman) Therapeutics to Expand Strategic Alliance with Cell and Gene Therapy Firm	13/09/23
2Seventy Bio, Inc. and Jw Therapeutics Announce Intent to Expand Strategic Partnership to Accelerate the Research and Development of T Cell-Based Immunotherapies and Autoimmune Therapies	12/09/23
JW Therapeutics Co. Ltd Announces Board Changes	30/08/23
JW Therapeutics' H1 Attributable Loss Narrows on Higher Revenue	29/08/23
JW Therapeutics Co. Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	29/08/23
JW (Cayman) Therapeutics to Buy Viral Vector from Substantial Shareholder	22/05/23
China Gives Investigational New Drug Clearance to JW Therapeutics' Anti-Lupus Injection; Shares Rise 7%	11/04/23
JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus	10/04/23
JW Therapeutics' 2022 Loss Widens	30/03/23
JW Therapeutics Co. Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	29/03/23
JW (Cayman) Therapeutics Initiates Clinical Study for B-Cell Lymphoma Injection	08/03/23
JW Therapeutics Co. Ltd. Announces Initiation of Clinical Study of Carteyva® in First-Line Treatment in Patients with High-Risk Large B-Cell Lymphoma	08/03/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues JW (Cayman) Therapeutics Co. Ltd

Actions

2126

KYG5210T1040

Autres langues

Filtres